12 June 2019 - The Ford government today announced it will be covering the cost of the drug Spinraza for most – but not all – patients with spinal muscular atrophy.
SMA is a rare disease that slowly destroys all the muscles in the body. It is the leading genetic cause of death in infants. OHIP will now cover Spinraza for patients with types 1, 2 and 3 – which are the most severe types of SMA – up until the age of 18.
In a statement Health Minister Christine Elliott writes, “Coverage for Spinraza is being expanded from the existing type 1 spinal muscular atrophy (SMA) patients to also include type 2 and 3 children and adolescents. Additionally, other patients with type 2 and 3 SMA may be considered on a case-by-case basis.”